VIEW MOREVHIO’s Director Josep Tabernero selected as a candidate for the AACR Board of Directors (2023-2026): voting now open
VIEW MOREOn the ground at ASCO GI Cancers Symposium: results from SUNLIGHT study point to practice-changing care for patients with refractory metastatic colorectal cancer
VIEW MORENAPOLI-3: NALIRIFOX shows promise as first-line therapy in patients with metastatic pancreatic ductal adenocarcinoma
Latest News
06 February 2023
New Research Project ODELIA launches to revolutionise Artificial Intelligence in Healthcare using Swarm Learning
The VHIO Radiomics Group participates in this new European project On January 1, 2023, a new EU-funded research project establishing...
31 January 2023
VHIO’s Director Josep Tabernero selected as a candidate for the AACR Board of Directors (2023-2026): voting now open
We are delighted to announce that our Director Josep Tabernero is among the selected candidates for the American Association for...
21 January 2023
On the ground at ASCO GI Cancers Symposium: results from SUNLIGHT study point to practice-changing care for patients with refractory metastatic colorectal cancer
Presented by VHIO’s Director Josep Tabernero during this week’s annual ASCO Gastrointestinal Cancers Symposium, January 19-21, results from the phase...
20 January 2023
NAPOLI-3: NALIRIFOX shows promise as first-line therapy in patients with metastatic pancreatic ductal adenocarcinoma
Metastatic Pancreatic Ductal Andenocarcinoma (mPDAC) is an aggressive type of cancer that is most frequently detected at advanced stages with...
Research Programs
PRECLINICAL & TRANSLATIONAL RESEARCH
Cellular Plasticity and Cancer Group
Our group focuses on the interplay between cellular plasticity, stem cells and cancer. Cellular plasticity is recognized today as a critical feature of cancer cells that enables them to transit between different cellular states, including reversible transitions.
PRECLINICAL & TRANSLATIONAL RESEARCH
Growth Factors Group
We focus our research on mechanisms of resistance to targeted therapies and most importantly, how to overcome it by showing that breast cancers resistant to T-DM1, an antibody-drug conjugate ADC)- can be efficiently treated with the second generation ADC SYD985 (Nadal-Serrano et al.).
CORE TECHNOLOGIES
Cancer Genomics Group
VHIO’s Cancer Genomics Group serves as a Core Technology laboratory. We are also dedicated to translational research as well as the development of novel genomic tests.
PRINCIPAL RESEARCHERS
Events
Friday 10 February 23 - 12:00 PM
scientific-seminars Seminars
Itay Tirosh | Dissecting intra-tumor heterogeneity by single cell RNA-seq
Thursday 16 February 23 - 11:00 AM
Patients
Cancer, menopause and sexuality. Myths and realities
Friday 24 February 23 - 12:00 PM
scientific-seminars Seminars
Chiara Ambrogio | Targeting KRAS: Pre-Clinical Validation & Therapeutic Perspectives to Overcome Drug Resistance
Thursday 9 March 23 - 11:00 AM
Patients
Legal doubts. What are the rights of breast cancer patients?
